Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Estrogen is scientifically validated for the treatment and prevention of osteoporosis, particularly in postmenopausal women. After menopause, the body’s natural production of estrogen drops significantly, leading to increased bone resorption and decreased bone formation. This hormonal change is a major contributor to the development of osteoporosis in women. Numerous randomized controlled trials and meta-analyses have demonstrated that estrogen therapy (either alone or as part of hormone replacement therapy, HRT) can significantly reduce bone turnover, increase bone mineral density (BMD), and lower the risk of vertebral and non-vertebral fractures in postmenopausal women.

Estrogen’s mechanism of action involves inhibiting the activity of osteoclasts, the cells responsible for bone resorption, thereby maintaining or increasing BMD. The Women’s Health Initiative and other large-scale studies have shown that estrogen therapy reduces the incidence of osteoporotic fractures. However, the use of estrogen is tempered by potential risks, including increased risk of breast cancer, venous thromboembolism, and stroke, leading to recommendations that it be used at the lowest effective dose for the shortest necessary duration in women at significant risk for osteoporosis and with intolerant or contraindicated alternative therapies.

In conclusion, the use of estrogen for osteoporosis is strongly supported by scientific evidence, though its risk-benefit profile must be carefully considered for each individual patient.

More about estrogen
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by estrogen

Products containing estrogen